Prostate News and Research

RSS

Cryoablation effective, safe, durable treatment for prostate cancer

Endocare today announced that 10-year follow-up data from a retrospective study demonstrated that cryoablation as a treatment for prostate cancer has a biochemical disease free survival rate of 77 percent.

14 Mar 2005

Tumor-targeted immune cells cure prostate cancer without causing systemic immune suppression

In a major breakthrough in cancer gene therapy, a Northwestern University researcher has endowed immune cells with the ability to specifically target metastatic prostate cancer in mice without causing the toxic immune suppression that has been associated with earlier forms of cancer gene therapy.

14 Mar 2005

David Lee, cancer cure director gets 10 year disqualification

A director of a company who used fear tactics and misleading advertising to sell vulnerable elderly people a 'cure' for prostate cancer has been disqualified from acting as a company director for 10 years following a DTI investigation.

7 Mar 2005

Prostate screenings could be used to encourage colon checks

Colon cancer is the third leading cause of cancer death in men, but according to a new University of Michigan Health System study, fewer than half of men surveyed were up-to-date with colon cancer screenings.

3 Mar 2005

Molecule from South American tree Quillaja, helps battle disease

The first synthesis of QS-21A, a medicinally important molecule that helps the body battle disease, has been achieved by chemists at the University of Illinois at Urbana-Champaign.

1 Mar 2005

Medical Services International signs $25 mil Chinese contract

Medical Services International has announced that it has signed a $25,500,000 US contract to supply the VScan HIV test kit in the People's Republic of China.

1 Mar 2005

Celebrex provides a two pronged attack against prostate cancer

Celecoxib, a selective COX-2 inhibitor with promising anti-cancer properties, has now been found to attack prostate cancer cells in a second way that differs from Vioxx (rofecoxib), another anti-inflammatory drug that also inhibits COX-2.

1 Mar 2005

Hormone therapy for prostate cancer can affect men's thinking

Androgen-deprivation therapy (AD), an effective therapy in the treatment of prostate cancer reduces levels of testosterone (a tumor stimulant), and estradiol, a form of estrogen, in men. These are known to be important in neurological development and play a particularly important role in the cognitive areas of learning and memory.

28 Feb 2005

Finasteride prevents prostate cancer

Recent finding show lives could be saved if men are given the drug Finasteride to prevent prostate cancer. New analysis of data from the Prostate Cancer Prevention Trial in the current issue of CANCER confirms this view. These results represent a milestone in cancer research, showing that prostate cancer could be prevented through drugs.

28 Feb 2005

Researchers identify target for cancer drugs

For nearly a decade, scientists have been trying to fully understand a particular communication pathway inside of cells that contributes to many malignant brain and prostate cancers. While scientists have identified elements of this pathway, other key components have remained a mystery.

23 Feb 2005

Beta blocker lowers blood pressure and wards off repeat heart attacks

A form of beta blocker, a drug commonly used to lower blood pressure and ward off repeat heart attacks, may provide the answer to preventing osteoporosis, said a Baylor College of Medicine researcher.

20 Feb 2005

When does occasional absentmindedness signal the start of memory decline?

Forgetfulness is something everyone experiences at one time or another, but at what point does it indicate the beginning of a serious memory loss?

17 Feb 2005

Single gene variant may increase a man's risk of prostate cancer by 50%

In 2001, Mount Sinai researchers published a study in Science that showed that a gene, known as KLF6, fails to function properly in at least 50 to 60 percent of all prostate cancers. This was the first single gene shown to be responsible for the majority of cases of this disease, which affects approximately 200,000 men each year.

16 Feb 2005

Why estrogenic hormones produce unintended results in women

New research is shedding light on why estrogenic hormones produce unintended results in women, giving hope to the idea that new drugs might reach their targets and work more effectively. Ultimately it could mean that postmenopausal women would know that hormone-replacement therapy would have only its intended result.

13 Feb 2005

Babies who weighed more at birth had higher rates of digestive and lymphatic cancers in adulthood

Medical experts have proposed associations between birth size and rates of adult cancer. To examine this hypothesis, researcher Valerie A. McCormack and colleagues at the London School of Hygiene & Tropical Medicine and the Universities of Uppsala and Stockholm investigated overall and site-specific cancer incidence in relation to birth characteristics in a Swedish population-based cohort.

7 Feb 2005

$Phenoxodiol gets fast track status for its intended use in patients with hormone-refractory prostate cancer$

Phenoxodiol gets fast track status for its intended use in patients with hormone-refractory prostate cancer

Marshall Edwards today announced that the U.S. Food and Drug Administration (FDA) has granted the investigational anti-cancer drug, phenoxodiol, fast track status for its intended use in patients with hormone- refractory prostate cancer (HRPC).

26 Jan 2005

Researchers discover way to overcome major hurdle in gene therapy for cancer

In a new study published in the Jan. 25 issue of the Proceedings of the National Academy of Sciences (PNAS), the researchers demonstrated that the technique works by incorporating it into a specially designed virus. The virus eradicated prostate cancer cells in the lab and in animals while leaving normal cells unscathed.

26 Jan 2005

Why some men develop aggressive prostate cancer that becomes resistant to hormone-withdrawal therapy

Researchers found that certain mutations in a protein called the androgen receptor cause advanced and invasive prostate cancer when put into otherwise healthy mice. The androgen receptor's normal function is to control growth of the prostate gland in response to cues from male hormones called androgens, which have long been thought to stimulate prostate tumors.

26 Jan 2005

Local environment directly influences adult stem cell reservoirs

Using the common fruit fly, researchers at UT Southwestern Medical Center have discovered that an intricate set of signals released by stem cells' surroundings governs their maintenance.

26 Jan 2005

New method of delivery of gene therapy may lead to safer treatment for cancer

The Lankenau Institute for Medical Research (LIMR) announced that in collaboration with the Massachusetts Institute of Technology (MIT) they have performed preclinical proof-of- principle studies showing how nanotechnology can be used to enhance gene therapy for cancer.

25 Jan 2005